Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pBABE-Src-Dasatinib-resistant Citations (5)

Originally described in: Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J Cancer Cell. 2009 Jul 7. 16(1):67-78.
PubMed Journal

Articles Citing pBABE-Src-Dasatinib-resistant

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Clin Cancer Res. 2012 Jul 1;18(13):3580-91. doi: 10.1158/1078-0432.CCR-11-3359. Epub 2012 May 14. PubMed
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. Oncogene. 2013 Nov 21;32(47):5429-38. doi: 10.1038/onc.2012.590. Epub 2013 Jan 14. PubMed
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Oncogenesis. 2018 Feb 28;7(2):23. doi: 10.1038/s41389-017-0015-5. PubMed
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Oncogene. 2019 Apr;38(14):2565-2579. doi: 10.1038/s41388-018-0617-1. Epub 2018 Dec 10. PubMed
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. Lima NC, Atkinson E, Bunney TD, Katan M, Huang PH. Int J Mol Sci. 2020 May 1;21(9). pii: ijms21093214. doi: 10.3390/ijms21093214. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.